Delving into the Latest Updates on Milatuzumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Humanised anti-CD74, Milatuzumab (USAN)

+ [2]

Target

CD74

Action

inhibitors

Mechanism

CD74 inhibitors(HLA-DR antigens-associated invariant chain inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Systemic Lupus Erythematosus

Inactive Indication

Acute Graft Versus Host DiseaseAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+ [11]

Originator Organization

Immunomedics, Inc.

Active Organization

Immunomedics, Inc.

Inactive Organization

Gilead Sciences, Inc.

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Sequence Code 13007608L

Source: *****

Sequence Code 9976219H

Source: *****

The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.

Start Date01 Aug 2012

Sponsor / Collaborator

Gilead Sciences, Inc.

NCT00989586

/ CompletedPhase 1/2IIT

A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.

Start Date01 Sep 2009

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Milatuzumab

Login to view more data

100 Translational Medicine associated with Milatuzumab

Login to view more data

100 Patents (Medical) associated with Milatuzumab

Login to view more data

34

Literatures (Medical) associated with Milatuzumab

01 Dec 2022·European Journal of Medicinal Chemistry

The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead

Article

Author: Conilh, Louise ; Boumendjel, Ahcène ; Falson, Pierre ; Dumontet, Charles ; Nguyen, Kim-Anh

The iron-dependent, non-apoptotic cell death, known as ferroptosis is an emerging strategy for the development of anticancer drugs. RSL3 was identified as an activator of ferroptosis through the inhibition of the glutathione peroxidase 4 (GPX4) which plays a crucial role in the cellular lipid oxidative stress. RSL3 is characterized by the presence of an electrophilic chloroacetyl moiety, namely warhead which covalently bonds to the catalytic and nucleophilic selenocysteine residue (Sec46) of GPX4. Like the major ferroptosis inducers, RSL3 suffers from lack of selectivity toward tumor cells. In this study, we report the first synthesis of an antibody-drug conjugate (ADC) containing RSL3 fragment and trastuzumab with the aim to deliver the agent selectively to tumors. The synthesis uses a judiciously chosen strategy to preserve the vital but fragile warhead. Full characterization of the ADC was accomplished, demonstrating the generation of a homogeneous DAR 8 conjugate. The robustness of the synthesis was successfully applied to another ADC associating the anti-CD74 mAb milatuzumab. The ADC induces ferroptotic cell death through reactive oxygen species accumulation and increases the activity of doxorubicin. The ADC associating trastuzumab and RSL3 may therefore offer potential applications in vectorized therapy alone or in combination with conventional chemotherapies.

01 Jul 2021·Annals of the Rheumatic DiseasesQ1 · MEDICINE

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

Q1 · MEDICINE

Letter

Author: Wegener, William A ; Goldenberg, David M ; Wallace, Daniel J ; Figueras, Florence

Milatuzumab (hLL1) is a humanised IgG1κ antibody that reacts with a cell surface epitope of human CD74, the human leukocyte antigen (HLA) class-II associated invariant chain present on antigen-presenting cells (APCs), including B cells and dendritic cells.1 Although initially studied for oncologic malignancies,2–5 dysregulation of APCs may also occur in non-malignant disorders, and several preclinical studies showed that milatuzumab modestly inhibited B cell proliferation, enhanced spontaneous migration, alterations of adhesion molecule expression and chemotaxis important for lymphocyte recruitment,6 and also reduced production of interferon-α in stimulated peripheral blood mononuclear cells isolated from healthy donors and patients with systemic lupus erythematosus (SLE) (unpublished results). Migration inhibitory factor (MIF) is a cytokine that activates a multicomponent receptor comprising the CD74 ligand-binding …

01 Jul 2018·British Journal of HaematologyQ2 · MEDICINE

A phase I‐II clinical trial of the anti‐CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach

Q2 · MEDICINE

Article

Author: Berrebi, Alain ; Haran, Michal ; Shevetz, Olga ; Valinsky, Liora ; Shvidel, Lev ; Amram, Orna ; Braester, Andrei ; Shtalrid, Mordechai ; Shachar, Idit ; Mordich, Orly ; Greenberg, Shulamit ; Herishanu, Yair ; Marom, Ayelet ; Ruchlemer, Rosa ; Harpaz, Nurith ; Mirkin, Vita ; Binsky‐Ehrenreich, Inbal ; Shtreiter, Marina

100 Deals associated with Milatuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08944	Milatuzumab	-	DB12943

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Lymphocytic Leukemia	Phase 2	United States	Gilead Sciences, Inc.	01 Aug 2008
Systemic Lupus Erythematosus	Phase 2	-	Immunomedics, Inc.	-
B-cell lymphoma refractory	Preclinical	United States	Gilead Sciences, Inc.	01 Sep 2009
Chronic lymphocytic leukaemia refractory	Preclinical	Israel	Gilead Sciences, Inc.	01 Apr 2009
B-Cell Malignant Neoplasm	Preclinical	United States	Gilead Sciences, Inc.	01 Jun 2007
Lupus Erythematosus, Discoid	Preclinical	United States	Immunomedics, Inc.	01 Jan 2007
Lupus Nephritis	Preclinical	United States	Immunomedics, Inc.	01 Jan 2007
Lupus Vasculitis, Central Nervous System	Preclinical	United States	Immunomedics, Inc.	01 Jan 2007
Multiple Myeloma	Preclinical	United States	Gilead Sciences, Inc.	01 Jan 2007
Plasmacytoma	Preclinical	United States	Immunomedics, Inc.	01 Jan 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00989586 (Pubmed \| Int J Radiat Oncol Biol Phys \| Br J Haematol) Manual	Phase 1/2	B-Cell Lymphoma	35	milatuzumab+veltuzumab	(mybqtohyjq) = ojauqbbngo boihhpowis (evknqirena ) View more	Positive	01 Jun 2015
				Veltuzumab 200 mg/m(2) weekly + Milatuzumab 16 mg/kg weekly	-

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Milatuzumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation